Drug intelligence / Profile preview

Acetylsalicylic acid + pseudoephedrine

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

Acetylsalicylic acid + pseudoephedrine is a fixed-dose combination of two active pharmaceutical ingredients: acetylsalicylic acid (commonly known as aspirin), a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-inflammatory properties, and pseudoephedrine, an alpha-adrenergic agonist that acts as a nasal decongestant. This combination is used for the symptomatic treatment of pain (such as headache or sore throat), fever, and nasal congestion associated with upper respiratory tract infections like the common cold or flu. Acetylsalicylic acid works by inhibiting cyclooxygenase enzymes COX-1 and COX-2 to reduce prostaglandin synthesis, thereby decreasing inflammation, pain sensitivity, and fever. Pseudoephedrine acts primarily on alpha adrenergic receptors to cause vasoconstriction in the nasal mucosa, reducing swelling and congestion[1][2][5][8]. Developers: Bayer

Brand names
Aspirin ComplexUrsinus
Other names
aspirin and pseudoephedrine
02

Targets

ADRB1 (β1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)ADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on Acetylsalicylic acid + pseudoephedrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acetylsalicylic acid + pseudoephedrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call